Stopping or extending immunoglobulin therapy to prevent infections
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been receiving immunoglobulin (Ig) therapy for at least 6 months to prevent bacterial infections due to low antibody levels.
- Your doctor has agreed that you are a good candidate to try stopping Ig therapy.
- You are willing to take one of the study treatments, including possibly switching to preventive antibiotics.
- You have not had a stem cell transplant, and you do not have a major infection in the last 3 months or an active infection now.
- You are not already taking daily antibiotics to prevent bacterial infections (other than for certain specific infections).
- You are not pregnant or breastfeeding, and you have not had your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This study compares two ways to help prevent infections after CAR-T cell therapy: regular antibody infusions (immunoglobulins) versus taking antibiotics. If you have low antibody levels after CAR-T treatment, this trial may help decide which approach works better for you.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.